肿瘤细胞治疗研究
ALL SOURCES
Next-generation antibody-based therapeutics in cancer: antibody-drug conjugates bispecific antibodies across hematologic malignancies and solid tumors
肿瘤学的治疗范式正在经历由抗体药物偶联物（ADC）和双特异性抗体（bsAb）驱动的深刻变革。
Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis.
我们确定了49项研究，共包含11,086名个体。
Antibody Response in Immunocompromised Patients With Hematologic Cancers Who Received a 3-Dose mRNA-1273 Vaccination Schedule for COVID-19.
本队列研究的结果支持，对于患有血液系统恶性肿瘤的免疫功能低下患者，初次接种计划应补充延迟的第三剂疫苗接种。B细胞淋巴瘤患者和异基因HCT受者需要在治疗或移植后重新接种疫苗。
Trends in Nephrology: From nihilism to targeted treatment of antibody-mediated rejection.
抗CD38抗体目前构成了治疗AMR证据最强的药物类别。
Delineating MYC-Mediated Escape Mechanisms from Conventional and T Cell-Redirecting Therapeutic Antibodies.
MYC 高表达的肿瘤细胞通过几种互不重叠的机制削弱了治疗性抗体的疗效。
γδ T cells in immunotherapies for B-cell malignancies.
尽管B细胞恶性肿瘤的治疗取得了进展，患者的长期生存率有所提高，但其中近一半的患者仍会复发。
Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis.
我们确定了49项研究，共包含11,086名个体。
CD137 (4-1BB) stimulation leads to metabolic and functional reprogramming of human monocytes/macrophages enhancing their tumoricidal activity.
免疫疗法开启了癌症治疗的新纪元。
The evolution of bispecific antibodies in multiple myeloma.
多发性骨髓瘤（MM）的治疗在过去十年中发生了革命性变化，随着靶向CD38的单克隆抗体如达雷妥尤单抗和伊沙妥昔单抗的问世，这些药物已被整合到新诊断或复发和/或难治性（R/R）MM患者的治疗武器库中。
A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma
这是一项早期 I 期注册临床试验，评估 CD19CAR-T 细胞治疗多发性骨髓瘤的安全性、可行性及初步疗效。当前状态：招募中。计划入组 12 例。试验地点：中国 · 上海（共 1 个中心，其中中国 1 个）。登记号：NCT06732232。
MEMBER ACCOUNT
登录成功会直接打开下一页。
